• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2026 04

02

TYK Medicines will present the research progress and results of 5 innovative drug projects at the 2026 Annual Meeting of American Association for Cancer Research (AACR 2026)

Discover More
2026 02

06

TYK Medicines’ New Drug for Brain Metastasis of Lung Cancer, Asandeutertinib, Has Marketing Application Accepted and Granted Priority Review

Discover More
2025 10

20

ESMO 2025 || TYK Medicines Releases Positive Clinical Data on Multiple CDK Inhibitors

Discover More
2025 08

14

TYK Medicines, Inc.’s EGFR-Targeted Innovative Drug Asandeutertinib Demonstrates Excellent Efficacy in NSCLC Patients with Brain Metastases — Interim Results from the ESAONA Pivotal Study Announced at WCLC 2025

Discover More
2025 04

24

Asandeutertinib (TY-9591) Submitted for Pre-New Drug Application

Discover More
2025 04

16

JTO Published Phase I Study Results of Asandeutertinib Mesylate Tablets

Discover More
12345>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号